PortalPublikationenOlanzapine or chlorpromazine plus lithium in first episode p...

Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial

Standard

Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. / Conus, P; Berk, M; Cotton, S M; Kader, L; Macneil, C; Hasty, M K; Hallam, K; Lambert, M; Murphy, B P; McGorry, P D.

in: EUR PSYCHIAT, Jahrgang 30, Nr. 8, 17.10.2015, S. 975-982.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Conus, P, Berk, M, Cotton, SM, Kader, L, Macneil, C, Hasty, MK, Hallam, K, Lambert, M, Murphy, BP & McGorry, PD 2015, 'Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial', EUR PSYCHIAT, Jg. 30, Nr. 8, S. 975-982. https://doi.org/10.1016/j.eurpsy.2015.09.009

APA

Conus, P., Berk, M., Cotton, S. M., Kader, L., Macneil, C., Hasty, M. K., Hallam, K., Lambert, M., Murphy, B. P., & McGorry, P. D. (2015). Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. EUR PSYCHIAT, 30(8), 975-982. https://doi.org/10.1016/j.eurpsy.2015.09.009

Vancouver

Conus P, Berk M, Cotton SM, Kader L, Macneil C, Hasty MK et al. Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial. EUR PSYCHIAT. 2015 Okt 17;30(8):975-982. https://doi.org/10.1016/j.eurpsy.2015.09.009

Bibtex

@article{6a752db936f24b5cb160a86d3de01dbb,
title = "Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial",
abstract = "BACKGROUND: Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments.METHODS: Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures.RESULTS: Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons.CONCLUSIONS: Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample.",
author = "P Conus and M Berk and Cotton, {S M} and L Kader and C Macneil and Hasty, {M K} and K Hallam and M Lambert and Murphy, {B P} and McGorry, {P D}",
note = "Copyright {\textcopyright} 2015 Elsevier Masson SAS. All rights reserved.",
year = "2015",
month = oct,
day = "17",
doi = "10.1016/j.eurpsy.2015.09.009",
language = "English",
volume = "30",
pages = "975--982",
journal = "EUR PSYCHIAT",
issn = "0924-9338",
publisher = "Elsevier Masson",
number = "8",

}

RIS

TY - JOUR

T1 - Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial

AU - Conus, P

AU - Berk, M

AU - Cotton, S M

AU - Kader, L

AU - Macneil, C

AU - Hasty, M K

AU - Hallam, K

AU - Lambert, M

AU - Murphy, B P

AU - McGorry, P D

N1 - Copyright © 2015 Elsevier Masson SAS. All rights reserved.

PY - 2015/10/17

Y1 - 2015/10/17

N2 - BACKGROUND: Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments.METHODS: Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures.RESULTS: Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons.CONCLUSIONS: Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample.

AB - BACKGROUND: Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments.METHODS: Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures.RESULTS: Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons.CONCLUSIONS: Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample.

U2 - 10.1016/j.eurpsy.2015.09.009

DO - 10.1016/j.eurpsy.2015.09.009

M3 - SCORING: Journal article

C2 - 26485297

VL - 30

SP - 975

EP - 982

JO - EUR PSYCHIAT

JF - EUR PSYCHIAT

SN - 0924-9338

IS - 8

ER -